Obsidian Therapeutics Inc D
D
OBX
13.840
USD
-0.11
(-0.79%)
Market Closed
Last updated: · Delayed 15 min
Volume
3,289
EPS
-4
Div Yield
-
P/E
-9
Market Cap
854,936,604
Title: Obsidian Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.